Although cognitive behavioral therapy (CBT) is an effective treatment for obsessive-compulsive disorder (OCD), with responder rates averaging 62% to 72%
1,2 a significant proportion of patients do not achieve satisfactory symptom relief. One possible way to further improve treatment efficacy is to enhance CBT with pharmacotherapy. Serotonin reuptake inhibitors are effective for OCD in their own right, but no synergistic effects of the 2 treatment modalities have been convincingly demonstrated compared with CBT alone.
3 One compound that has shown promise as an adjunct to CBT for OCD is d-cycloserine (DCS).
4 It affects the glutamate system by acting as a partial agonist at the
N-methyl-d-aspartate (NMDA) receptor, which is crucially implicated in fear learning and fear extinction in both rats and humans.
4 Specifically, NMDA antagonists block fear extinction in rats, whereas NMDA agonists enhance fear extinction.
5 In CBT for OCD, patients gradually face anxiety-provoking cues and simultaneously refrain from carrying out rituals, an approach known as
exposure with response prevention (ERP).
6 As ERP is based on the principles of fear extinction, DCS may be a viable augmentation strategy for these patients. To date, 3 of 5 randomized clinical trials of DCS-augmented CBT for OCD have found that DCS augmentation may lead to a faster treatment response than placebo, but results are inconsistent as to whether DCS is superior to placebo at posttreatment or follow-up.
7-11 However, these previous trials had modest sample sizes (N = 24-30) and may therefore have been underpowered to detect subtle differences between DCS and placebo. Additional variables such as number of CBT sessions, the dose and number of DCS capsules, the timing of drug administration, and the success of the exposure sessions may also contribute to the conflicting results obtained to date.
12-14